PT DIAGNOS LABORATORIUM UTAMA TBK PT Diagnos Laboratorium Utama Tbk Share Price
Equities
DGNS
ID1000158702
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 334 IDR | -1.76% |
|
+1.83% | +35.77% |
| Sales 2022 | 193B 11.96M 999M | Sales 2023 | 146B 9.03M 755M | Capitalization | 308B 19.06M 1.59B |
|---|---|---|---|---|---|
| Net income 2022 | 12.66B 785K 65.6M | Net income 2023 | -13.66B -847K -70.74M | EV / Sales 2022 | 1.49 x |
| Net cash position 2022 | 17.27B 1.07M 89.48M | Net Debt 2023 | 42.77B 2.65M 222M | EV / Sales 2023 | 2.4 x |
| P/E ratio 2022 |
24.1
x | P/E ratio 2023 |
-22.5
x | Employees | 64 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.76% | ||
| 1 week | +1.83% | ||
| Current month | +7.05% | ||
| 1 month | +7.05% | ||
| 3 months | +26.52% | ||
| 6 months | +19.29% | ||
| Current year | +35.77% |
1 week
318.00
354.00
1 month
300.00358.00
Current year
236.00436.00
1 year
160.00436.00
3 years
160.001 485.00
5 years
160.001 485.00
10 years
160.001 485.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mesha Rizal Sini
CEO | Chief Executive Officer | 50 | 13/20/13 |
Fergus Richard
DFI | Director of Finance/CFO | 33 | 20/22/20 |
Dilly Dwiasri
COO | Chief Operating Officer | 47 | 20/22/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ivan Rizal Sini
CHM | Chairman | 52 | 13/20/13 |
| Director/Board Member | 53 | 13/20/13 | |
| Director/Board Member | 53 | 30/23/30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 340 | +1.80% | 7,123,200 |
| 30/24/30 | 334 | -1.76% | 8,490,900 |
| 29/24/29 | 340 | +1.19% | 4,400,200 |
| 26/24/26 | 336 | +0.60% | 3,008,900 |
| 25/24/25 | 334 | +1.21% | 10,283,000 |
End-of-day quote INDONESIA S.E., April 30, 2024
More quotes
PT Diagnos Laboratorium Utama Tbk is an Indonesia-based company that is engaged in providing health services using laboratories. The Companyâs scope of activities also includes private clinical activities. Its products and services include clinical pathology laboratory tests, anatomical pathology laboratory tests, genomics laboratory tests, homecare health tests, corporate health tests and Covid-19 tests. Its clinical pathology laboratory provides services ranging from molecular examinations to support more treatment. Its clinical pathology laboratory provides services for examination of hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology and microbiology. The services provided at the genetic laboratory are non-invasive prenatal testing (NIPT), preimplantation genetic testing for aneuploidy (PGT-A) services, and preimplantation genetic testing for monogenic diseases (PGT-M) services. Its homecare health services provide health checks that are done at home.
Calendar
15/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +35.77% | 26.36M | |
| -18.61% | 8.15B | |
| +48.66% | 3.82B | |
| -8.06% | 2.47B | |
| -38.71% | 2.46B | |
| -10.12% | 2.34B | |
| -9.02% | 1.88B | |
| -19.29% | 1.55B | |
| -40.78% | 1.21B | |
| +8.32% | 1.11B |
- Stock Market
- Equities
- DGNS Stock
